You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials

Citation Tools

Article menu

Download PDFPDF

Oral Presentations
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Jesus D, Henriques C, Matos A, et al
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
Lupus Science & Medicine 2024;11:doi: 10.1136/lupus-2024-el.31